---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-087841"
form_type: "8-K"
ticker: "LITS"
cik: "0001262104"
company_name: "Lite Strategy, Inc."
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T14:59:19.061271+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MEI Pharma halts voruciclib clinical development, begins strategic alternatives review

## Summary
- Board unanimously decided to evaluate strategic alternatives including potential transactions or orderly wind-down.
- Clinical development of voruciclib discontinued; only certain non-clinical activities will continue.
- Company intends to maximize value of its assets; no specific timeline or deal announced.
- Corporate presentation attached as Exhibit 99.1 details voruciclib program status.

## SEC filing metadata
- accession: 0000950170-24-087841
- form_type: 8-K
- ticker: LITS
- cik: 0001262104
- company_name: Lite Strategy, Inc.
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1262104/000095017024087841/0000950170-24-087841-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1262104/000095017024087841/meip-20240730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-087841
- JSON: https://secwatch.observer/filing/0000950170-24-087841.json
- Plain text: https://secwatch.observer/filing/0000950170-24-087841.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.